<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161041</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0239</org_study_id>
    <nct_id>NCT03161041</nct_id>
  </id_info>
  <brief_title>Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study</brief_title>
  <official_title>Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis - French Part of the Main Bev-IP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit&#xD;
      from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However,&#xD;
      even after optimal cytoreduction, systemic and locoregional recurrence are common.&#xD;
      Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients.&#xD;
      The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with&#xD;
      colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study&#xD;
      evaluates whether perioperative chemotherapy including BEV in combination with CRS and&#xD;
      oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite&#xD;
      endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity,&#xD;
      pathological response, progression free survival, and overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    CHU Lyon will join as a participating center (and as national French coordinator) as a part of&#xD;
    the BEV-IP study ongoing study EudraCT-number 2014-004257-14.&#xD;
  </why_stopped>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related Adverse events grade IIIb or higher grade as assessed by Dindo-Clavien classification</measure>
    <time_frame>Until 3 months after surgery and intraperitoneal chemotherapy</time_frame>
    <description>Major morbidity (grade IIIb or higher grade complication according to Dindo-Clavien classification)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatement related Adverse events less than grade IIIb as assessed by Dindo-Clavien classification</measure>
    <time_frame>Until 3 months after surgery and intraperitoneal chemotherapy</time_frame>
    <description>Minor morbidity (less than grade IIIb complication according to Dindo-Clavien classification).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential chemotherapy related morbidity</measure>
    <time_frame>During the first 60 postoperative days</time_frame>
    <description>Adverse events will be described using MedDRA terms (version 18.0) and graded according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>calculated from date of surgery until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>Time interval between date of surgery and disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab</measure>
    <time_frame>Day 1 after termination of the cytoreductive surgery</time_frame>
    <description>Scored with a 3 level regression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>Using the EORTC QLQ-C30 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment completion rate</measure>
    <time_frame>Day 1 after termination of adjuvant chemotherapy</time_frame>
    <description>Percentage of patients receiving all planned courses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>Using SF 36 questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and CRS with oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive surgery combined with HIPEC</intervention_name>
    <description>Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).</description>
    <arm_group_label>Bevacizumab and CRS with oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).</intervention_name>
    <description>bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).</description>
    <arm_group_label>Bevacizumab and CRS with oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  biopsy proven adenocarcinoma of the colon or rectum and synchronous or metachronous&#xD;
             peritoneal carcinomatosis.&#xD;
&#xD;
          -  absence of systemic disease, with the exception of small, superficial liver&#xD;
             metastases, requiring only minor surgery.&#xD;
&#xD;
          -  resectable disease at staging, during laparoscopic evaluation and during exploration&#xD;
             for cytoreductive surgery and intraperitoneal chemotherapy.&#xD;
&#xD;
          -  complete macroscopic cytoreduction at the time of surgery (CC-0/1)&#xD;
&#xD;
          -  good general health status (Karnofsky index &gt; 70%)&#xD;
&#xD;
          -  expected life expectancy more than 6 months&#xD;
&#xD;
          -  no other malignancy than disease under study&#xD;
&#xD;
          -  serum creatinine &lt; 1.5 mg/dl or a calculated GFR â‰¥ 60 mL/min/1.73 m2&#xD;
&#xD;
          -  serum total bilirubin &lt; 1.5 mg/dl&#xD;
&#xD;
          -  platelet count &gt; 100,000/ml&#xD;
&#xD;
          -  hemoglobin &gt; 9g/dl&#xD;
&#xD;
          -  neutrophil granulocytes &gt; 1,500/ml&#xD;
&#xD;
          -  International Normalized Ration (INR) 2 or &lt; 2&#xD;
&#xD;
          -  Absence of alcohol and/or drug abuse&#xD;
&#xD;
          -  No inclusion in other clinical trials interfering with the study protocol&#xD;
&#xD;
          -  No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          -  Absence of heart failure (NYHA 2 or &gt; 2) or significant coronary artery disease&#xD;
&#xD;
          -  No pregnancy or breast feeding&#xD;
&#xD;
          -  Adequate contraception in fertile patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No written informed consent&#xD;
&#xD;
          -  Tumour in the presence of obstruction&#xD;
&#xD;
          -  Evidence of extra-abdominal disease or extensive liver metastasis&#xD;
&#xD;
          -  Peritoneal cancer index &gt; 25&#xD;
&#xD;
          -  Active bacterial, viral or fungal infection&#xD;
&#xD;
          -  Active gastro-duodenal ulcer&#xD;
&#xD;
          -  Parenchymal liver disease (any stage cirrhosis)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Severe obstructive or restrictive respiratory insufficiency&#xD;
&#xD;
          -  Psychiatric pathology capable of affecting comprehension and judgment faculty&#xD;
&#xD;
          -  Known allergy to oxaliplatin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytoreductive surgery, HIPEC, perioperative chemotherapy, peritoneal carcinomatosis, bevacizumab, colorectal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

